{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:35Z","timestamp":1790720375789,"version":"4.1.0"},"reference-count":31,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,3,12]]},"published-print":{"date-parts":[[2025,6]]},"DOI":"10.2967\/jnumed.124.269389","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T17:15:28Z","timestamp":1745514928000},"page":"900-908","source":"Crossref","is-referenced-by-count":13,"title":["Multicycle Dosimetric Behavior and Dose\u2013Effect Relationships in [<sup>177<\/sup>Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy"],"prefix":"10.2967","volume":"66","author":[{"given":"Gunjan","family":"Kayal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly E.","family":"Roseland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellen","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mirando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Kit","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuni K.","family":"Dewaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"2025060410151047000_66.6.900.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2025060410151047000_66.6.900.2","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","article-title":"Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry","volume":"44","author":"Sundl\u00f6v","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151047000_66.6.900.3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the PPRRT trial","volume":"46","author":"Del Prete","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151047000_66.6.900.4","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30290-9"},{"key":"2025060410151047000_66.6.900.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265987"},{"key":"2025060410151047000_66.6.900.6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00259-024-06863-y","article-title":"The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE","volume":"52","author":"Maccauro","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151047000_66.6.900.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267023"},{"key":"2025060410151047000_66.6.900.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266991"},{"key":"2025060410151047000_66.6.900.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262069"},{"key":"2025060410151047000_66.6.900.10","unstructured":"Supporting patient care, AminoProtect. Fagron Sterile Services website. https:\/\/www.fagronsterile.com\/newsroom\/aminoprotect-npd. Published April 6, 2022. Accessed March 24, 2025."},{"key":"2025060410151047000_66.6.900.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263738"},{"key":"2025060410151047000_66.6.900.12","first-page":"S253","article-title":"Evaluation of a novel hybrid intensity and gradient-based method for PET tumor segmentation using a Monte Carlo simulated NSCLC phantom","volume":"45","author":"Wan","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151047000_66.6.900.13","doi-asserted-by":"publisher","DOI":"10.1118\/1.2836421"},{"key":"2025060410151047000_66.6.900.14","unstructured":"CKD-EPI Creatinine Equation (2021). National Kidney Foundation website. https:\/\/www.kidney.org\/ckd-epi-creatinine-equation-2021. Accessed March 24, 2025."},{"key":"2025060410151047000_66.6.900.15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.diii.2014.05.002","article-title":"Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson","volume":"95","author":"Fournier","year":"2014","journal-title":"Diagn Interv Imaging."},{"key":"2025060410151047000_66.6.900.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1985.tb07117.x"},{"key":"2025060410151047000_66.6.900.17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12022-020-09623-4","article-title":"Histopathological and immunophenotypic changes of pancreatic neuroendocrine tumors after neoadjuvant peptide receptor radionuclide therapy (PRRT)","volume":"31","author":"Schiavo Lena","year":"2020","journal-title":"Endocr Pathol."},{"key":"2025060410151047000_66.6.900.18","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/cancers13050962","article-title":"Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE: differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms","volume":"13","author":"Jahn","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2025060410151047000_66.6.900.19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13550-024-01163-w","article-title":"Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study","volume":"14","author":"Danieli","year":"2024","journal-title":"EJNMMI Res."},{"key":"2025060410151047000_66.6.900.20","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00259-024-06963-9","article-title":"EANM expert opinion: how can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed doses","volume":"52","author":"Pouget","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151047000_66.6.900.21","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00259-023-06257-6","article-title":"The relationship between tumour dosimetry, response, and overall survival in patients with unresectable neuroendocrine neoplasms (NEN) treated with 177Lu DOTATATE (LuTate)","volume":"50","author":"Alipour","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151047000_66.6.900.22","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s12094-018-1881-9","article-title":"Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors","volume":"20","author":"Merino-Casabiel","year":"2018","journal-title":"Clin Transl Oncol."},{"key":"2025060410151047000_66.6.900.23","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00259-019-04601-3","article-title":"PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest","volume":"47","author":"Bodei","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151047000_66.6.900.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.231480"},{"key":"2025060410151047000_66.6.900.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"},{"key":"2025060410151047000_66.6.900.26","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2012.1195"},{"key":"2025060410151047000_66.6.900.27","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","article-title":"Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning","volume":"45","author":"Cremonesi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151047000_66.6.900.28","doi-asserted-by":"crossref","first-page":"1009358","DOI":"10.3389\/fmed.2022.1009358","article-title":"Biological variation and reference change value of the estimated glomerular filtration rate in humans: a systematic review and meta-analysis","volume":"9","author":"Th\u00f6ni","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"2025060410151047000_66.6.900.29","doi-asserted-by":"crossref","unstructured":"Halfdanarson TR Reidy DL Vijavergia N . Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors [abstract]. J Clin Oncol. 40(suppl 4):S514.","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS514"},{"key":"2025060410151047000_66.6.900.30","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet."},{"key":"2025060410151047000_66.6.900.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266843"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.269389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T17:16:58Z","timestamp":1749057418000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.269389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,2]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.2967\/jnumed.124.269389"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.269389","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}